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Among the autoimmune diseases that affecthuman blood, hemolytic anemia and autoim-mune thrombocytopenia are the most frequent
and the best known from a diagnostic and therapeutic
point of view. More seldom, autoantibodies may
develop against components of the hemostasis system.
Some of them neutralize proteins involved in the reg-
ulation of thrombus formation, causing acquired
thrombotic tendencies due to autoantibodies inactivat-
ing naturally occurring anticoagulants such as protein
C and protein S,1,2 or the von Willebrand factor cleav-
ing protease ADAMTS13.3,4 On the other hand,
autoantibodies directed against procoagulant factors
cause a bleeding tendency, such as acquired hemophil-
ia A due to the development of anti-factor VIII (FVIII)
autoantibodies (autoantibodies against procoagulant
factors other than FVIII are rare).5
Acquired hemophilia has a yearly incidence of no
more than one case per million in the general popula-
tion, and affects not only patients with pre-existing
autoimmune diseases (systemic lupus erythematosus,
rheumatoid arthritis, myasthenia, Sjogren syndrome,
hyperthyroidism and others) but also (and more fre-
quently) previously healthy people. Typically, there
are two peaks of age of onset of acquired hemophilia:
in the young adult, mainly in women who develop this
complication in the post-partum period; and in the eld-
erly, usually with no underlying disease.5 Acquired
hemophilia is much more clinically severe than con-
genital hemophilia, and is more difficult to diagnose,
also because cases are seen in an array of clinical set-
tings that are not usually equipped to tackle them.
Even the specialized center, however, sees a very lim-
ited number of cases, so that is difficult to acquire a
truly wide experience in acquired hemophilia. It is not
surprising, therefore, that nine experts from three con-
tinents chose to put together their experiences in an
article meant to provide consensus recommendations
on the diagnosis and treatment of acquired hemophil-
ia.6 Their recommendations are clear and concise, and
our only major disagreement regards the writing of a
similar manuscript for non-specialist physicians. We
disagree, because the only useful advice that can be
given to them is to refer the patient immediately to the
closest hematology center. With no major disagree-
ment with Huth-Hühne et al.,6 we chose to compare
their recommendations for the treatment of bleeding
episodes and eradication of the autoantibodies with
those made very recently by Franchini and Lippi in a
“How I Treat“ article in Blood.7
Treatment of bleeding in acquired hemophilia
Both the articles recommend bypassing agents as
first-line therapy, and both list recombinant activated
factor VII (rFVIIa) and factor VIII inhibitor bypassing
activity (FEIBA) as the products of choice. The recom-
mended dosages and schedules of administration are
very similar: bolus injections of rFVIIa, 90 µg/kg every
2-3 hours (Franchini and Lippi mention the possible
usage of dosages up to 120 µg/kg),7 and 50-100 U/kg
FEIBA every 8 to 12 hours, (Huth-Kühne et al.6 recom-
mend not exceeding a maximum daily dosage of 200
IU/Kg). On the whole, it would appear that both the
agents are able to control as many as 80-90% of bleed-
ing episodes (spontaneous and post-traumatic), even
though there is no face-to-face comparison. The rec-
ommended bolus dosages are similar, even though the
authors’ choice is mainly transferred from the experi-
ence gained with congenital hemophilia complicated
by FVIII inhibitors (alloantibodies). In the latter, the
current prevailing regimen, supported by randomized
trials,8,9 is to give a single large dose (270 µg/kg) rather
than repeated smaller doses. It would be of interest to
use this high-dosage bolus regimen also in acquired
hemophilia, even though in these severe patients, who
are almost always admitted to hospital, the use of a
single dose is not as critically convenient as it is for
home self-treatment in congenital hemophilia. The
international group mentions the possibility of using
sequentially both rFVIIa and FEIBA, but the experience
gained in congenital hemophilia with this combination
is still too small to postulate its use in acquired hemo-
philia. According to the reports in the literature, there
is little evidence in favor of either product over the
other, but Franchini and Lippi7 declare their preference
for rFVIIa for a higher perceived viral safety. Both
products are indeed convincingly safe, but rFVIIa does
not cause the anamnestic response of anti-FVIII, some-
times observed after FEIBA that contains some FVIII.
Lack of an anamnestic response is not so critical in
acquired hemophilia as it is in congenital disease,
because in the latter a rise in inhibitor titer may render
difficult or delay the start of eradication through
immune tolerance. Finally, both the articles state that
the risk of thrombotic complications, owing to the
hypercoagulable state induced by both rFVIIa and
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FEIBA, is greater in acquired hemophilia than in con-
genital hemophilia, due to the older age of the patients
and the thrombotic tendency often associated with the
underlying clinical conditions. 
Both the articles are also proposing, but with lower
priority, methods of treatment that increase FVIII to
levels capable of overcoming the inactivation exerted
by the autoantibody, and both discuss the role of FVIII
containing concentrates. This treatment is recommend-
ed only when the antibody level is low, and Franchini
and Lippi7 set the threshold at 5 Bethesda units. Both
the articles recommend a loading dose of FVIII, tailored
upon the antibody titer and meant to neutralize it, fol-
lowed by additional doses meant to increase plasma
FVIII to the levels necessary to handle any bleeding
episode. In the context of low-titer antibodies,
Franchini and Lippi7 are more enthusiastic than Huth-
Kühne et al.6 on the use of desmopressin, given at the
standard dose of 0.3 µg/kg for 3-5 days. 
We agree with their favorable experience in a few
selected cases.
Inhibitor eradications
Both the articles state that attempts to eradicate the
inhibitor should be aggressively pursued, owing to the
severity of bleeding episodes and the costs and risks
associated with the forementioned treatments.
Franchini and Lippi7 point out very appropriately that
the first attempt to attain this goal is the cure of the
associated condition or disease, that would lead to the
disappearance of the inhibitor. This approach is not
easily applicable in the absence of an underlying con-
dition or disease, as in the elderly, but is typically
applicable in the post-partum period. Even though it
may take several weeks after delivery for the inhibitor
to disappear, a conservative approach based upon the
actual and prompt treatment of bleeding is warranted
in these women, and any attempt to eradicate the anti-
body with immunosuppressive agents should be def-
ered and ultimately implemented only in the rare cases
of persisting antibodies. Other diseases in which the
antibody may disappear upon treatment are some
hematologic malignancies, solid cancers, inflammato-
ry bowel disease and drug-associated cases. However,
as mentioned above, the antibodies developing in eld-
erly patients with no underlying diseases are the epit-
ome of those that warrant eradication with immuno-
suppressive agents. This therapeutic approach is justi-
fied by the high risk of death due to intracranial and
retroperitoneal bleeding in these frail elderly individu-
als, but a balance must always be made with the con-
comitant risk of immunosuppression and related infec-
tions. 
Both the articles emphasize that antibody eradica-
tion is the only aspect of the management of acquired
hemophilia that is evidence-based, albeit only on the
results of a small randomized trial of 31 patients.10
They were initially treated with prednisone at a daily
dose of 1 mg/kg for three weeks, and more than one-
third responded with the eradication of the antibody.
Patients unresponsive after the initial course were then
randomized to receive the same dose of prednisone for
six additional weeks, oral cyclophosphamide alone (2
mg/kg per day) or cyclophosphamide plus prednisone. 
Approximately half of the patients initially unre-
sponsive to prednisone alone responded to one of the
two cyclophosphamide regimens. The only significant
contribution after this seminal study comes from a
non-randomized but large surveillance study carried
out in the United Kingdom by Collins et al.,11 who
found no significant difference between patients treat-
ed from the onset with steroids alone, or with a com-
bination of steroids and other immunosuppressive
agents. With these studies as background, the recom-
mendations of Franchini and Lippi7 and those of Huth-
Kühne et al.6 are similar. Both favor the combination of
daily prednisone (1 mg/kg) plus cyclophosphamide
(1.5-2 mg) for at least four weeks. We definitely prefer
to start with corticosteroids alone for at least one
month, and to resort to cyclophosphamide only in
case of failure, because we were appalled by recent
data that infections related to the use of immunosup-
pressive agents are the main cause of death in patients
with acquired hemophilia.12 More recently, there has
been an increasing tendency to use rituximab for erad-
ication therapy, usually after failure of the foremen-
tioned immunosuppressive regimens but sometimes
also as first therapy.13 Several reports of single cases or
small series give promising results, using the dosages
and the schemes of treatment adopted in patients with
B-cell non–Hodgkin’s lymphomas. Eradication of the
inhibitor was observed in approximately 90% of
cases, even though the follow-up was usually too
short to rule out re-appearance of the autoantibody
when B-cells circulate again. In both the foremen-
tioned articles6,7 rituximab is recommended as second-
line therapy only if cyclophosphamide and/or corti-
costeroids have failed or were contraindicated. We
agree with these recommendations, because rituximab
is very expensive and not without side effects, besides
being used off-label in acquired hemophilia.
Conclusions 
Acquired hemophilia is so rare that it is unlikely that
large randomized therapeutic trials will ever be feasible
in this severe and life-threatening disease. The avail-
able data are usually based on case reports or small
uncontrolled trials, or on review articles that turn out to
be as informative as the small studies that have gener-
ated them. Hence, it is convenient for the general
hematologist that two recent articles6,7 produced by an
array of recognized experts make similar therapeutic
recommendations. Some progress can be expected in
the near future. We are not convinced that the larger
and more-evidence based use of rituximab will sub-
stantially change the rate of eradication of the autoan-
tibodies, already high with the means currently avail-
able. In terms of treatment of bleeding episodes, we
hope that the forthcoming availability of recombinant
B-domainless FVIII of porcine origin, that is usually
poorly inactivated by human autoantibodies,14 will
increase the number of patients that can be effectively
treated with replacement therapy of the deficient coag-
ulation factor.
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